Tizona Therapeutics
Biotechnology company that developed immuno-oncology therapeutics targeting immune checkpoints to enhance anti-tumor immune responses. Acquired by Arcus Biosciences.
Notes
Tizona Therapeutics was a biotechnology company focused on developing immuno-oncology therapeutics. The company was headquartered in South San Francisco, California.
Tizona developed therapeutics targeting immune checkpoints and other mechanisms to enhance the body's anti-tumor immune response. The company's approach focused on novel targets in the tumor microenvironment that could complement existing checkpoint inhibitors.
The company was part of the Abingworth portfolio.
Acquired by Arcus Biosciences, which integrated Tizona's pipeline and capabilities into its immuno-oncology platform.
Team
- Historical leadership (company acquired)
Additional Research Findings
- Part of Abingworth portfolio
- Immuno-oncology focus
- Immune checkpoint targeting
- South San Francisco, California headquarters
- Founded in 2014
- Acquired by Arcus Biosciences
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Abingworth | London, UK / Boston, USA | biotech-focused | seedseries-a+3 | 34 |